Problem

DeepScribe addresses the administrative burden of clinical documentation: clinicians must convert complex patient conversations into complete, billable records while maintaining face-to-face attention. This burden contributes to burnout and can undermine patient care; it also has direct economic consequences because time spent documenting reduces clinical capacity, while accurate, timely notes can support billing and practice revenue. The pain is particularly acute in community oncology, where care complexity, coordination needs, and emotional demands are high.

The clearest “killer” use case is an oncology clinician who needs to document a detailed visit without spending additional time after the encounter typing or dictating notes. DeepScribe’s own materials also position the product for urology, cardiology, and other specialties, suggesting that the core problem is broad but that specialty medicine—especially oncology—is its initial wedge.

Product / Service

DeepScribe is an ambient AI clinical workflow platform that listens to patient visits as they happen, extracts medically relevant information, and turns the conversation into specialty-specific clinical notes. The resulting documentation is written directly into the appropriate fields of the clinician’s electronic health record, producing complete, billable records without requiring the physician to manually reconstruct the encounter afterward.

The benefit is a more natural patient interaction, less documentation work, and improved operational performance for practices and healthcare organizations. DeepScribe describes its audience as ranging from small private practices to large healthcare organizations, and its workflow is designed to reduce burnout, support patient care, and potentially increase revenue through more efficient documentation.

Market

DeepScribe competes in ambient AI medical scribing and the broader clinical documentation, healthcare workflow, NLP, and health-tech software markets. The supplied research does not identify individual competitors by name, so the most defensible characterization is that DeepScribe competes with other AI scribe and clinical documentation platforms, as well as incumbent documentation workflows embedded in electronic health record systems.

The company is clearly commercial rather than pre-revenue, although the available revenue figure is a third-party estimate: GetLatka reports approximately $14.6 million in 2025 estimated ARR and about 133 employees as of 2026, while also noting that it does not have customer-count information. DeepScribe was founded in 2017 and Forge reports $59.19 million raised to date, including a $24 million Series B announced on January 3, 2024. Its public positioning around specialty medicine and its reported use across 90% of community oncology centers indicate meaningful traction in oncology, though the exact customer count and independently verified revenue are not available in the supplied sources.